Research from the Hebrew University of Jerusalem has unveiled potential therapeutic applications for compounds found in cannabis, particularly cannabidiol (CBD) and cannabigerol (CBG). The study, published in the British Journal of Pharmacology, indicates that these compounds may offer new avenues for addressing metabolic dysfunction-associated steatotic liver disease (MASLD), a common chronic liver disorder affecting roughly one-third of adults globally.
Implications for Chronic Liver Health
MASLD is mainly associated with obesity and insulin resistance, and currently has limited pharmaceutical treatment options. Patients mostly depend on difficult-to-maintain lifestyle changes to manage the condition. The researchers found that both CBD and CBG can reduce liver fat and improve metabolic health in experimental models, which could signal a breakthrough in how metabolic diseases are treated.
Joseph Tam, director of the Multidisciplinary Center for Cannabinoid Research at Hebrew University and lead author of the study, emphasized the discovery of a new mechanism through which these compounds enhance liver function. The study suggests that CBD and CBG fortify the liver’s energy management by creating what researchers call a “backup battery.” This is accomplished through increased levels of phosphocreatine, a molecule that stores energy and can help sustain liver operations, particularly under stress from a high-fat diet.
Mechanisms of Action
The research highlights a process termed “metabolic remodeling,” through which CBD and CBG effectively enhance energy production and waste management in liver cells. Notably, these compounds restored the functioning of enzymes called cathepsins, which play a crucial role in breaking down harmful fats and waste substances in cellular recycling centers.
The study indicates that the improved activity of these cellular “cleaning crews” enables better clearance of dangerous lipids, such as triglycerides and ceramides, known for triggering inflammation. While both cannabinoids demonstrated efficacy, the results were particularly promising with CBG, which appeared to be more effective in reducing total body fat and improving insulin sensitivity.
Public Health and Economic Context
The findings hold significant implications for public health policy, especially considering the rising prevalence of metabolic diseases like MASLD. With the lack of effective medications, there is a pressing need for innovative solutions. If substantiated in human clinical trials, the use of plant-derived cannabinoids could alleviate the burden on healthcare systems by providing alternative therapies that improve liver health without the intoxicating side effects associated with THC, the psychoactive compound in cannabis.
The economic impact of such advancements could be substantial, potentially reducing healthcare costs associated with chronic liver diseases while improving overall quality of life for affected individuals. Furthermore, the transition from traditional pharmaceuticals to plant-based treatments may encourage additional research and development in the burgeoning field of cannabinoid-based medicine.
Limitations and Future Research Directions
Despite the encouraging outcomes, the researchers caution that these results stem from controlled laboratory environments. More extensive clinical trials involving human subjects will be essential to determine appropriate dosages, long-term effects, and the overall viability of CBD and CBG as medical treatments.
Recent literature has also underscored concerns regarding the comprehensive use of cannabis in medical settings. A systematic review published in JAMA analyzed over 2,500 studies, revealing gaps between public expectation and the empirical evidence surrounding cannabis use for various medical conditions. While there are clear benefits for certain FDA-approved cannabinoid medications—like those used to treat nausea in cancer patients—much of the public perception surrounding the effectiveness of cannabis remains unsubstantiated by high-quality clinical data.
Healthcare professionals advise individuals considering cannabinoid treatments to consult with their doctors to discuss potential risks and benefits. As research evolves, a more nuanced understanding of cannabis’s therapeutic potential may transform how healthcare practitioners approach metabolic diseases and offer new strategies for patient care.
In summary, the recent study on CBD and CBG represents a promising step toward reshaping treatment paradigms for chronic liver conditions. However, rigorous further research will be necessary to validate these findings and ensure their application in human health contexts.
Source reference: Full report
About The Author
